Stockreport

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements [Yahoo! Finance]

Aspire Biopharma Holdings, Inc.  (ASBP) 
PDF multi-faceted patent-pending drug delivery technology, received notice (the "Notice") on December 11, 2025, from the Nasdaq Listing Qualifications Panel (the "Hearings P [Read more]